Tempus AI (NASDAQ:TEM) Sees Strong Trading Volume – Here’s Why

Tempus AI, Inc. (NASDAQ:TEM) shares saw strong trading volume on Thursday . Approximately 6,078,808 shares were traded during mid-day trading, an increase of 1% from the previous session’s volume of 6,037,241 shares.The stock last traded at $79.8320 and had previously closed at $69.97.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: CEO commentary outlining Tempus AI’s growth strategy and projected Medicare revenue has strengthened confidence that reimbursement expansion could provide a significant new revenue stream. Tempus AI Stock Roars Back 92% From July Low After CEO Lays Out Growth Plan
• Positive Sentiment: Morgan Stanley’s updated outlook reportedly incorporated additional reimbursement-driven revenue potential, helping fuel a sharp weekly advance in TEM shares and reinforcing the bullish growth narrative. Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
• Positive Sentiment: Trading momentum remains strong: shares have rebounded roughly 92% to 95% from the July low, with market capitalization moving above $14 billion. Above-average volume and elevated call-option activity indicate substantial speculative interest. Tempus AI Stock Is Soaring
• Neutral Sentiment: Analysts and market commentators are assessing whether the recent surge can continue. The rally has improved sentiment, but the sharp move also raises the risk of profit-taking and increased volatility. Strength Seen in Tempus
• Negative Sentiment: Zacks cautioned that recent earnings-estimate revision trends may not support another near-term advance, while brokerages maintain an average “Hold” rating. Tempus also remains unprofitable, making the stock particularly sensitive to valuation concerns and changes in growth expectations. Tempus AI Receives Average Hold Rating

Analyst Ratings Changes

TEM has been the subject of several research reports. TD Cowen restated a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Stifel Nicolaus cut their price objective on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a research note on Monday, August 3rd. Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Lake Street Capital cut shares of Tempus AI to a “hold” rating in a report on Monday, July 20th. Finally, Needham & Company LLC restated a “buy” rating and set a $75.00 target price on shares of Tempus AI in a research report on Friday, July 31st. Eleven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $69.33.

Tempus AI Price Performance

The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The stock has a fifty day simple moving average of $57.19 and a 200-day simple moving average of $52.90. The company has a market capitalization of $14.04 billion, a price-to-earnings ratio of -54.06 and a beta of 3.72.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. During the same period in the previous year, the firm earned ($0.22) EPS. The business’s quarterly revenue was up 21.6% on a year-over-year basis. On average, equities research analysts anticipate that Tempus AI, Inc. will post -1.38 EPS for the current year.

Insider Buying and Selling at Tempus AI

In other news, CEO Ryan Fukushima sold 41,095 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $2,038,722.95. Following the sale, the chief executive officer directly owned 562,463 shares of the company’s stock, valued at $27,903,789.43. This represents a 6.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric P. Lefkofsky sold 250,000 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $42.06, for a total value of $10,515,000.00. Following the sale, the chief executive officer owned 200,000 shares in the company, valued at $8,412,000. This trade represents a 55.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,254,701 shares of company stock valued at $73,877,392. Corporate insiders own 24.26% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds have recently bought and sold shares of the business. Amova Asset Management Americas Inc. increased its position in shares of Tempus AI by 1.2% in the fourth quarter. Amova Asset Management Americas Inc. now owns 3,504,823 shares of the company’s stock valued at $206,960,000 after buying an additional 41,728 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after buying an additional 821,490 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Tempus AI by 8.2% during the 4th quarter. Geode Capital Management LLC now owns 1,870,510 shares of the company’s stock valued at $110,478,000 after buying an additional 141,680 shares in the last quarter. Franklin Resources Inc. grew its stake in Tempus AI by 27.9% in the 4th quarter. Franklin Resources Inc. now owns 1,861,782 shares of the company’s stock valued at $109,938,000 after acquiring an additional 405,662 shares during the period. Finally, Lingotto Investment Management LLP grew its stake in Tempus AI by 45.9% in the 4th quarter. Lingotto Investment Management LLP now owns 1,143,526 shares of the company’s stock valued at $67,525,000 after acquiring an additional 359,667 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.